Can unicorns float? Is a hot dog a sandwich? And how are drug companies like gas stations?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we dive into Moderna (MRNA) Therapeutics’ ambition to pull off the biggest IPO in biotech history at a time when the sector is having a hard time convincing investors of its promise. Then, STAT’s Casey Ross joins us to talk about his investigation into lockstep price increases for a pair of blockbuster drugs and the effects they have on patients. Finally, biopharma veteran and Yumanity Therapeutics CEO Dr. Tony Coles sits down to talk about his career, the future of neuroscience, and burner Twitter accounts.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy